I am an Associate professor and director of research in Kidney transplantation at Yale University School of Medicine. My research has focused on mechanisms of proteinuria and renal fibrosis underlying GWAS-identified genetic variants and non-HLA mismatches that also associate with allograft CKD. Our group has experience with human biopsy tissue and blood RNA/ DNA assays, PBMC evaluations, and morphometry applied to cohort studies. Using genotype-phenotype information from two prospective cohort studies we evaluated outcomes of APOL1-risk genotype transplant recipients and identified a novel immunologic role for APOL1 risk variants (CKD-associated variant in African-ancestry). Currently we are investigating this T-cell phenotype using novel Bac-transgenic mouse models, and its relevance to FSGS. My current research funding includes NIDDK for my work on SHROOM3, the role of AMPK signaling as a “switch” modulating podocyte survival between Minimal change disease and FSGS, from the Dept of Defense to study APOL1-variant Tcells.
31 MARCH 2023
Time |
Session |
|
15:45
16:45
|
Sinee Disthabanchong
Chairperson
Faculty of Medicine, Ramathibodi Hospital, Mahidol UniversityThailand
-
Podocyte-specific NUP160 Knockout Mice Develop Nephrotic Syndrome and Glomerulosclerosis
-
Q and A
-
Comparison of Serum Sodium Following Intravenous Fluid Isotonic and Hypotonic Solution in Younger Children: A Randomized Controlled Trial
-
Q and A
-
Vitamin B Complex in Patients with Acute Kidney Injury The Vibaki Trial
-
Q and A
-
BAC-transgenic mice show a novel T-cell intrinsic role for FSGS-associated APOL1 risk-variants in T-cell activation
Madhav MENON
Free Communication
Yale School of MedicineUnited States
-
Q and A
-
Distribution, Preparedness and Management of Ukrainian Adult Refugees on Dialysis
Dmytro IVANOV
Free Communication
National Medical UniversityUkraine
-
Q and A
-
SGLT2 Inhibitor Treatment May Enhance Kidney Oxygenation and Attenuate HIF1A Expression in Young Persons with Type 2 Diabetes
Viji Nair
Free Communication
University of Michigan Medical CenterUnited States
-
Q and A
MR 110
|